# Saffron Anxiety Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/saffron-anxiety-randomized-trial-evidence-review
Category: evidence-review
Summary: Saffron Anxiety Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are system
Last reviewed: 2026-05-27
Reviewed by: Migaku Evidence Review
# Saffron Anxiety Randomized Trial: What the Evidence Says

## Quick Answer

Saffron Anxiety Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Adverse Events of Saffron ( Crocus sativus L.): Systematic Review of Current Evidence | systematic review | 1 | 2026-04-27 | 10.1002/hsr2.72212 |
| Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks | narrative review | 3 | 2026-02-28 | 10.3390/ph19030399 |

## What The Sources Report

- Difficulties in accessing healthcare, their high costs, personal preferences, and the perceived safety of medicinal herbs have contributed to the increased usage of herbalism. [Hasheminasab Fatemeh Sadat (2026); evidence level 1]
- Given their popularity, it is crucial to have up-to-date risk and benefit assessments on these herbal products. [Hasheminasab Fatemeh Sadat (2026); evidence level 1]
- Although these products are available without a prescription and are generally thought to be safe, there are pharmacological and toxicological risks associated with their use. [Căuș Maria-Nina (2026); evidence level 3]
- The differences in the regulatory framework allow for broad consumer access to plant-based products; it also creates potential gaps in safety monitoring and risk communication. [Căuș Maria-Nina (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For saffron anxiety randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Hasheminasab Fatemeh Sadat (2026). Adverse Events of Saffron ( Crocus sativus L.): Systematic Review of Current Evidence. DOI: 10.1002/hsr2.72212. PMCID: PMC13121846. PMID: 42057871. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13121846/
- Căuș Maria-Nina (2026). Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks. DOI: 10.3390/ph19030399. PMCID: PMC13028908. PMID: 41901246. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13028908/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.